Richard Goldberg / Julian Lonbay (eds.)

Pharmaceutical Medicine, Biotechnology and European Law

Herausgeber: Goldberg, Richard; Lonbay, Julian

• Gebundenes Buch

Produktbeschreibung

European law has been faced with increasingly complex issues emerging from rapid developments in pharmaceutical medicine and biotechnology. A team of distinguished European legal practitioners and academics reassess the impact of European law on health care and pharmaceutical law. The essays are grouped under four themes: Free movement of goods and persons, competition and intellectual property; European drug regulation; Biotechnology; and Product liability and transnational health care litigation. The book reviews the impact of European law on movement of health care professionals and pharmaceuticals, patent and trademark rights, the Product Liability Directive, laws on product liability and intellectual property claims. It examines recent developments in drug regulation, particularly data protection, abridged applications for marketing authorisations and the European Medicines Evaluation Agency. A compelling analysis is made of the Biotechnology Directive morality clauses. This important study offers a valuable resource for the pharmaceutical and biotechnology industries, legal academics and practitioners alike.

Table of contents:
Part I. Free Movement of Goods and Persons, Competition and Intellectual Property: 1. The free movement of goods I: pharmaceuticals, patents and parallel trade Professor W. R. Cornish; 2. The free movement of goods II: pharmaceuticals, trade marks and parallel imports Belinda Isaac; 3. The free movement of health care professionals in the European Community Julian Lonbay; 4. EC competition law, drugs and intellectual property: recent developments Professor Leigh Hancher; Part II. European Drug Regulation: 5. Data protection and abridged applications for marketing authorisations in the pharmaceutical industry Ian Dodds-Smith; 6. The role of the European Medicines Evaluation Agency (EMEA) in the harmonisation of pharmaceutical regulation Antoine Cuvillier; Part III. Biotechnology: 7. The morality clauses of the Directive on the Legal Protection of Biotechnological Inventions: conflict, compromise, and the patent community Deryck Beyleveld, Professor Roger Brownsword and Margaret Llewelyn; Part IV. Product Liability and Transnational Health Care Litigation: 8. The development risk defence and the European Court of Justice; increased injury costs and the Supplementary Protection Certificate Richard Goldberg; 9. Transnational health care litigation and the Private International Law (Miscellaneous Provisions) Act 1995, Part III Jonathan Harris.

A team of distinguished European legal practitioners and academics reassess the impact of European law on health care and pharmaceutical law. This important study presents four themes: Free movement of goods and persons, competition and intellectual property; European drug regulation; Biotechnology; and Product liability and transnational health care litigation.

Lawyers and academics reassess the impact of European law on health care and pharmaceutical law.

Produktdetails

• Verlag: Cambridge University Press
• Seitenzahl: 280
• Erscheinungstermin: 31. März 2006
• Englisch
• Abmessung: 235mm x 157mm x 21mm
• Gewicht: 611g
• ISBN-13: 9780521792493
• ISBN-10: 0521792495
• Artikelnr.: 21310645

Autorenporträt

Dr Richard Goldberg is a Solicitor and Lecturer in Law at the Faculty of Law of the University of Birmingham. He is the author of Causation and Risk in the Law of Torts: Scientific Evidence and Medicinal Product Liability, nominated for the SPTL Book Prize in 1999.

Inhaltsangabe

Notes on the contributors; Preface; Introduction Richard Goldberg and
Julian Lonbay; Part I. Free Movement of Goods and Persons, Competition and
Intellectual Property: 1. The free movement of goods I: pharmaceuticals,
patents and parallel trade Professor W. R. Cornish; 2. The free movement of
goods II: pharmaceuticals, trade marks and parallel imports Belinda Isaac;
3. The free movement of health care professionals in the European Community
Julian Lonbay; 4. EC competition law, drugs and intellectual property:
recent developments Professor Leigh Hancher; Part II. European Drug
Regulation: 5. Data protection and abridged applications for marketing
authorisations in the pharmaceutical industry Ian Dodds-Smith; 6. The role
of the European Medicines Evaluation Agency (EMEA) in the harmonisation of
pharmaceutical regulation Antoine Cuvillier; Part III. Biotechnology: 7.
The morality clauses of the Directive on the Legal Protection of
Biotechnological Inventions: conflict, compromise, and the patent community
Deryck Beyleveld, Professor Roger Brownsword and Margaret Llewelyn; Part
IV. Product Liability and Transnational Health Care Litigation: 8. The
development risk defence and the European Court of Justice; increased
injury costs and the Supplementary Protection Certificate Richard Goldberg;
9. Transnational health care litigation and the Private International Law
(Miscellaneous Provisions) Act 1995, Part III Jonathan Harris; Index.